Toxoplasma chorioretinitis
ICD-10 B58.0 is a billable code used to indicate a diagnosis of toxoplasma chorioretinitis.
Toxoplasma chorioretinitis is an ocular condition caused by the protozoan parasite Toxoplasma gondii. This infection is particularly significant in immunocompromised individuals, such as those with HIV/AIDS, and can lead to severe visual impairment or blindness if left untreated. The parasite is typically acquired through ingestion of oocysts found in contaminated food or water, or through contact with infected cat feces. In pregnant women, Toxoplasma can cross the placenta and infect the fetus, leading to congenital toxoplasmosis, which may present with chorioretinitis among other symptoms. Clinically, patients may present with blurred vision, floaters, and scotomas. Diagnosis is often confirmed through serological testing for Toxoplasma antibodies and imaging studies such as fundus examination or OCT (Optical Coherence Tomography) to visualize retinal lesions. Treatment typically involves the use of pyrimethamine and sulfadiazine, along with folinic acid to mitigate side effects. Early diagnosis and intervention are crucial to prevent irreversible damage to the retina.
Detailed ocular examination findings, imaging results, and treatment plans.
Patients presenting with visual disturbances, especially in immunocompromised individuals.
Documentation must clearly indicate the cause of chorioretinitis and any associated systemic conditions.
Comprehensive patient history, serological test results, and treatment protocols.
Patients with HIV/AIDS presenting with opportunistic infections.
Must document the patient's immune status and any co-infections.
Used when a new patient presents with symptoms suggestive of chorioretinitis.
Complete ocular examination findings and history.
Ophthalmologists should ensure thorough documentation of visual acuity and fundoscopic findings.
Common symptoms include blurred vision, floaters, and scotomas. Patients may also experience pain and redness in the eye.
Diagnosis is typically made through serological testing for Toxoplasma antibodies and imaging studies such as fundus examination.
Treatment usually involves a combination of pyrimethamine and sulfadiazine, along with folinic acid to reduce side effects.
